Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Can-Fite BioPharma Management

Management Kriterienprüfungen 4/4

Can-Fite BioPharma's CEO ist Motti Farbstein , ernannt in Aug 2003, hat eine Amtszeit von 20.33 Jahren. Die jährliche Gesamtvergütung beträgt $471.00K , bestehend aus 63.3% Gehalt und 36.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0% der Aktien des Unternehmens, im Wert von ₪29.76 . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 20.3 Jahre bzw. 15.3 Jahre.

Wichtige Informationen

Motti Farbstein

Geschäftsführender

US$467.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	66.4%
Amtszeit als Geschäftsführer	20.8yrs
Eigentum des Geschäftsführers	0.00008%
Durchschnittliche Amtszeit des Managements	20.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	15.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Motti Farbstein im Vergleich zu den Einnahmen von Can-Fite BioPharma verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	US$467k	US$310k	-US$8m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$471k	US$298k	-US$10m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$484k	US$291k	-US$15m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$468k	US$313k	-US$15m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$17m
Mar 31 2020	n/a	n/a	-US$13m
Dec 31 2019	US$277k	US$195k	-US$13m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$8m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	US$331k	US$186k	-US$7m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$315k	US$242k	-US$6m

Vergütung im Vergleich zum Markt: MottiDie Gesamtvergütung ($USD471.00K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt IL ($USD444.90K).

Entschädigung vs. Einkommen: MottiDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Motti Farbstein (59 yo)

20.8yrs

Amtszeit

US$467,000

Vergütung

Mr. Motti Farbstein serves as a Chief Operating and Financial Officer at Can-Fite BioPharma Ltd. since May 2005 and serves as its Chief Executive Officer since June 30, 2023. Mr. Farbstein served as Chief...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Pnina Fishman	Founder	18.7yrs	US$703.00k	0.018% $ 7.4k
Motti Farbstein	CEO and Chief Financial & Operating Officer	20.8yrs	US$467.00k	0.000080% $ 33.5
Sari Fishman	Vice President of Business Development	10.3yrs	US$373.00k	keine Daten
Ilan Cohn	Co-Founder & Director	29.7yrs	keine Daten	0.0089% $ 3.7k
Stephen A. Harrison	Member of Clinical Advisory Board & Consulting Chief Medical Officer	less than a year	keine Daten	keine Daten

20.8yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von CANF ist erfahren und erfahren (durchschnittliche Amtszeit: 20.3 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Pnina Fishman	Founder	18.7yrs	US$703.00k	0.018% $ 7.4k
Ilan Cohn	Co-Founder & Director	30.3yrs	keine Daten	0.0089% $ 3.7k
Stephen A. Harrison	Member of Clinical Advisory Board & Consulting Chief Medical Officer	no data	keine Daten	keine Daten
Nabil Hanna	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Yaacov Goldman	External Independent Director	6.8yrs	US$60.00k	keine Daten
Abraham Sartani	Independent Director	23.3yrs	keine Daten	keine Daten
Guy Regev	Independent External Director	12.8yrs	US$60.00k	0.0016% $ 679.1
Scott L. Friedman	Member of Clinical Advisory Board	no data	keine Daten	keine Daten
Arun Sanyal	Member of Clinical Advisory Board	no data	keine Daten	keine Daten
Yoseph Bornstein	Independent External Director	2.8yrs	keine Daten	keine Daten
Rifaat Safadi	Member of Clinical Advisory Board	no data	keine Daten	keine Daten
Kim Papp	Member of Clinical Advisory Board	no data	keine Daten	keine Daten

15.8yrs

Durchschnittliche Betriebszugehörigkeit

69yo

Durchschnittliches Alter

Erfahrener Vorstand: CANFDie Vorstandsmitglieder sind sehr erfahren ( 15.3 ).

Can-Fite BioPharma Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Insufficient new directors

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Insufficient new directors

Can-Fite BioPharma Ltd., Annual General Meeting, Dec 09, 2020

Recent updates

Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024

New minor risk - Share price stability

Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Insufficient new directors

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Can-Fite BioPharma Ltd. Completes Patient Enrollment in Phase III Psoriasis Study

Second quarter 2021 earnings released: US$0.006 loss per share (vs US$0.013 loss in 2Q 2020)

Can-Fite BioPharma Ltd Receives Notice of Patent Allowance in China for NASH Treatment

No longer forecast to breakeven

Can-Fite Biopharma Ltd. to Initiate Phase IIb Nash Study with its Drug Candidate Namodenoson

Can-Fite BioPharma Ltd. Provides Clinical Update

First quarter 2021 earnings released: US$0.004 loss per share (vs US$0.025 loss in 1Q 2020)

No longer forecast to breakeven

Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely

Can-Fite Biopharma Ltd. Announces That 75% of Patients Enrolled in Its Phase III Comfort Study